How to Cite
Abstract
In the open, comparative, non-randomized and prospective study conducted from 2007 to 2014 there were included 83 patients who received combined treatment for thoracic esophageal cancer. For a comparative analysis there was used a retrospective control group of 51 patients with esophageal cancer who had undergone surgery alone from 1999 to 2014. Complex treatment of patients with advanced forms of thoracic esophageal cancer included argon-plasma recanalization of the lumen of the esophagus followed by neoadjuvant chemoradiotherapy in two versions. One group of patients (29) received external beam radiotherapy, prescription dose of 40-45 Gy, the other group of patients (54) received intraluminal brachytherapy, 3 sessions of 7 Gy, prescription dose of 21 Gy. All patients synchronously with radiotherapy there were performed two cycles of polychemotherapy on PF scheme. A month after the neoadjuvant treatment there was carried out resection of the esophagus with simultaneous plastics by gastric stem. Complete local tumor regression was achieved in 34,7% of patients in group with intraluminal brachytherapy and 30% in the group with external beam radiotherapy. Long-term results could be traced in 90.8% of patients. Using chemoradiotherapy on preoperative stage we managed to increase disease-free and overall survival of patients with an increase of median of progression-free survival - 27 against 12 months and overall survival - 29 against 14 months in comparison with surgery alone.References
Канаев С.В., Тюряева Е.И., Левченко Е.В., Дворецкий С.Ю., Щербаков А.М., Аванесян А.А. Значение внутрипросветной брахитерапии в лечении рака пищевода // Вопр. онкол. - 2015. - Т. 61. - № 1. - С. 34-39
Мерабишвили В.М. Выживаемость онкологических больных. Выпуск второй. Часть 1. / Под ред. проф. Ю.А. Щербука. - СПб., 2011. - 329 с.
Мерабишвили В.М. Заболеваемость, смертность и анализ эффективности организации онкологической помощи больным раком пищевода // Вопр. онкол. - 2013. - Т. 59. - № 1. - С. 30-40.
Минимальные клинические рекомендации Европейского Общества Медицинской Онкологии (ESМО) / Редакторы русского перевода: проф. С. А. Тюляндин, к.м.н. Д. А. Носов; проф. Н. И. Переводчикова, - М.: Издательская группа РОНЦ им. H. Н. Блохина РАМИ, 2010. - 436 с.
Онкология: национальное руководство / Под. ред. В.И. Чиссова, М.И. Давыдова. - М.: ГЭОТАР - Медиа, 2008. - 1072 с.
Ariga Т., Ogawa K., Shimoji H. et al. Radical Radiotherapy for Superficial Esophageal Cancer: Impact of Clinical N Stage on Survival // Anticancer Research. - 2012. - Vol. 32. - P 3371-3376.
Bosset J.F., Gignoux M., Triboulet J.P. et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus // N. Engl. J. Med. - 1997. - Vol. 337. - P 161-167.
Eldeeb H., Reza S., Shmueli U. et al. External beam radiotherapy versus brachytherapy in the management of malignant oesophageal dysphagia: a retrospective study // J. BUON - 2012. - Vol. 17 (3). - P 508-511.
Ferlay J., Shin H.R., Bray F. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 // Int. J. Cancer. - 2010. - Vol.127. - P 2893-2917.
Gaspar L.E., Winter K., Kocha W.I. et al. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report // Cancer. - 2000. -Vol. 88. - P. 988-995.
Gebski V., Burmeister B., Smithers B.M. et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis // Lancet Oncol. - 2007. - Vol. 8. - P. 226-234.
Ghosh S., Sau S., Mitra S. et al. Palliation of dysphagia in advanced, metastatic or recurrent carcinoma oesophagus with high dose rate intraluminal brachytherapy--an eastern Indian experience of 35 cases // J. Indian Med. Assoc. - 2012. - Vol. 110 (7). - P. 449-452.
Jin H.L., Zhu H., Ling T.S. et al. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis // World J. Gastroenterol. - 2009. - Vol. 15 (47). - P 5983-5991.
Kranzfelder M., Schuster T., Geinitz H. et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer // Br. J. Surg. - 2011. - Vol. 98. - P. 768-783.
McKenzie S., Mailey B., Artinyan A. et al. Improved Outcomes in the Management of Esophageal Cancer with the Addition of Surgical Resection to Chemoradiation Therapy // Annals of Surgical Oncology - 2011. - Vol. 18. - P. 551-558.
Muijs C. T., Beukema J. C., Mul V. E. et al. External beam radiotherapy combined with intraluminal brachytherapyin esophageal carcinoma. Radiotherapy and Oncology. - 2012. - Vol. 102. - P. 303-308.
Raval M., Zouain N. The effectiveness of high dose rate brachytherapy using a special applicator set with external beam radiation treatment and chemotherapy followed by surgery as a treatment of adenocarcinoma of the esophagus: A case series of single institution with literature review // J. of Can. Research and Experimental Oncol. - 2011. - Vol. 3. - P 1-7.
Sjoquist K.M., Burmeister B.H., Smithers B.M. et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis // Lancet Oncology - 2011. - Vol. 12. - P 681-692.
Sur R.K., Levin C.V., Donde B. et al. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma--an International Atomic Energy Agency study // Int. J. Radiat. Oncol. Biol. Phys. - 2002. - Vol. 53 (1). - P. 127-133.
Tepper J., Krasna M.J., Niedzwiecki D. et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 // J. Clin. Oncol. -2008. - Vol. 26. - P. 1086-1092.
Urschel J.D., Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer // Am. J. Surg. - 2003. -Vol. 185. - P 538-543.
Vuong T., Szego P., David M. et al. The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy // Int. J. Radiation Oncology Biol. Phys. -2005. - Vol. 63. - № 3. - P. 758-764.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...